Intraperitoneal injection of maximally effective doses of corticotropin Corticotropin (ACTH) increases adrenal polyphosphoinositides (1), which, by virtue of their polyphosphorylated polar head groups, stimulate mitochondrial pregnenolone synthesis (2), the rate-determining step in steroidogenesis (3). We have shown (4) that (i) adrenal polyphosphoinositide concentrations correlate closely with steroidogenesis in various experimental conditions and (ii) cycloheximide, a protein-synthesis inhibitor that blocks ACTH effects on steroidogenesis (5), also inhibits new effects of ACTH on adrenal polyphosphoinositides and rapidly reverses such on-going effects. We also have observed in in vitro studies (6) that the ACTH-induced increase in polyphosphoinositides is preceded by increases in their precursors, phosphatidylinositol and phosphatidic acid, and that cycloheximide also blocks these effects of ACTH. Our results suggested that ACTH rapidly increases adrenal phosphatidic acid by a cycloheximide-sensitive process and that this leads to rapid increases in mono and.polyphosphoinositides and other derivatives of CDP-diacylglycerol (e.g., phosphatidylglycerol).
tides and corticosterone within 5-15 min. Continued maximal adrenal stimulation by ACTH1-18) treatment caused sustained increases in adrenal phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, polyphosphoinositides, and corticosterone. Treatment with cycloheximide during this steady-state caused rapid decreases in all of these substances to basal levels. The observed half-lives of adrenal phosphatidic acid, phosphatidylinositol, polyphosphoinosities, pioshatidylglycerol, and corticosterone during cycloheximide inhibition were 0.15, 1.0, 1.7, 3.3, and 3.5 mm, respectively. Calculated production rates during maximal ACTH stimulation were 1060,991,90, 34, and 41 nmol/g of tissue per min, respectively. These findings suggest that (i) an initial effect of ACTH on de novo synthesis of phosphatidic acid can account for all subsequently observed increases in other phospholipid derivatives of CDP-diacylglycerol, (ii) a labile protein is required for the ACTH-induced increase in phosphatidic acid, (ji) the phosphatidate-mpolyphosphoinositide-polyglycerophospholipid pathway is rapidly and dramatically responsive to hormonal stimulation, (iv) changes in steroidogenesis correlate well with changes in this phospholipid pathway, and (v) stimulation of this pathway is rapidly reversible.
Corticotropin (ACTH) increases adrenal polyphosphoinositides (1) , which, by virtue of their polyphosphorylated polar head groups, stimulate mitochondrial pregnenolone synthesis (2) , the rate-determining step in steroidogenesis (3) . We have shown (4) that (i) adrenal polyphosphoinositide concentrations correlate closely with steroidogenesis in various experimental conditions and (ii) cycloheximide, a protein-synthesis inhibitor that blocks ACTH effects on steroidogenesis (5), also inhibits new effects of ACTH on adrenal polyphosphoinositides and rapidly reverses such on-going effects. We also have observed in in vitro studies (6) that the ACTH-induced increase in polyphosphoinositides is preceded by increases in their precursors, phosphatidylinositol and phosphatidic acid, and that cycloheximide also blocks these effects of ACTH. Our results suggested that ACTH rapidly increases adrenal phosphatidic acid by a cycloheximide-sensitive process and that this leads to rapid increases in mono and.polyphosphoinositides and other derivatives of CDP-diacylglycerol (e.g., phosphatidylglycerol).
In this study we examined the rates of increase and decrease of adrenal phosphatidic acid, the inositides, phosphatidylglycerol, and steroidogenesis during stimulation by ACTH and inhibition by cycloheximide in vivo. The latter treatment provided a unique opportunity to determine turnover and
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with (8)], and the phospholipids in the remainder were extracted as described (1) . Phospholipids were purified by thin-layer chromatography with solvent system B as described (1) phoinositide were 0.95, 0.90, 0.80, 0.70, 0.52, 0.32, and 0.06, respectively. System C was used only to purify phosphatidic acid and phosphatidylglycerol, and RF values were 0.50 and 0.30, respectively. Inositides and phosphatidylserine were examined only in system B. Phosphatidylglycerol was generally determined in system C and only occasionally in system B after it had been cleanly separated from phosphatidylethanolamine and phosphatidylcholine. Both systems were used for phosphatidic acid, and results were virtually the same in both systems. Results were used only when substances were cleanly separated. Recoveries of all phospholipids were approximately 50% and were not influenced by treatments. Other methods for chromatography, lipid localization, and quantification of phosphorus by colorimetry have been described (1) .
Both ACTH preparations were kindly provided by Organon. Cycloheximide and phospholipid standards were obtained from Sigma. Thin-layer chromatography plates (silica gel with 5% magnesium acetate) were obtained from Supelco, Bellefonte, PA.
RESULTS
Adrenal phosphatidic acid increased rapidly to maximal or near-maximal levels within 2 min of ACTH(1-24) injection ( Fig. 1 ). In other experiments not shown, maximal levels were attained within 1.5 min (including 30 sec after injection and 60 sec between decapitation and adrenal removal). Phosphatidylglycerol and phosphatidylinositol increased in parallel slightly more slowly and reached maximal levels after 4-6 min. Polyphosphoinositides increased gradually over the course of this experiment, and there was remarkable parallelism between the production of these substances and adrenal corticosterone. The timing of the peak response of polyphosphoinositides varied somewhat from experiment to experiment, ranging from 5 to 15 min (4), but in all cases either preceded or coincided with the peak response of adrenal corticosterone.* Long-acting ACTH(1-18) treatment evoked sustained maximal increases in steroidogenesis (adrenal corticosterone), polyphosphoinositides, phosphatidylinositol, phosphatidylglycerol, and phosphatidic acid, and nearly steady-state conditions prevailed between 60 and 180 min (Fig. 2) .
When cycloheximide was injected into rats previously treated for 60 min with long-acting ACTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (Fig. 3) , adrenal corticosterone returned to the control range after 20 min, and inositides and phosphatidic acid returned to control or lower levels by 6 and 2 min, respectively. On the other hand, phosphatidylserine, a derivative of phosphatidylethanolamine, was metabolically stable and did not decrease with cycloheximide treatment. In other experiments (not shown) phosphatidylglycerol decreased to basal over a 6-min period. Fig. 1 (t 1/2) of serum corticosterone, adrenal corticosterone, and adrenal polyphosphoinositides were 10, 3.5, and 1.7 min, respectively.t From these values (Table 1) , the fractional turnover rate and total turnover rate at zero-time cycloheximide treatment could be calculated. The latter is equal to the production rate during maximal ACTH stimulation because steady-state conditions prevailed.
To obtain earlier time points for decay of phosphatidylinositol and phosphatidic acid during cycloheximide blockade, experiments were conducted with more frequent sampling during the first 3.5 min. Phosphatidic acid, phosphatidylinositol, and phosphatidylglycerol decreased curvilinearly during this time period. When plotted semilogarithmically, the decreases followed first-order kinetics, the t ACTH, through cyclic AMP, increases de novo synthesis of polyphosphoinositides. The same sequence is observed in inphosphatidic acid, either from fatty acyl-CoA and sn-glyccubations of adrenal quarters (6), but more time (2-to 3-fold) erol-3'-PO4 or from a nonphospholipid source of 1,2-diacylis required to achieve maximal levels of phospholipids and glycerol and ATP. This suggestion (regarding a de novo insteroidogenesis in vitro. crease) seems likely because ACTH also increases phosphati-
The ACTH-induced, steady-state increases in adrenal dylcholine and all or most phospholipids by a cycloheximidephospholipids and corticosterone and their first-order decay sensitive process (11); therefore, it is improbable that ACTH rates during the cycloheximide blockade provided a unique increases phosphatidate at the expense of a decrease in other opportunity to estimate their fractional turnover and production phospholipids or 1,2-diacylglycerol.t
The rapidity of the increase in phosphatidic acid and de-* Alternatively, it is possible that ACTH could increase (and cyclorivatives of CDP-diacylglycerol after AGTH treatment in vivo heximide decrease) the conversion of "metabolically inactive"
is remarkable. Phosphatidic acid is maximal within 1.5-2 min, 1,2-diacylglycerol to phosphatidic acid and use of the phosphatidphosphatidylglycerol and phopatdlio,,to,are.maximalat ate-polyphosphoinositide-polyglycerophospholipid pathway to phosphatidylglycerol andl phosphatidylinositol are maximal at generate "metabolically active" 1,2-diacylglycerol and ultimately 4-6 min, and polyphosphoinositides are maximal at 5-15 min.
phosphatidylcholine, phosphophatidylethanolamine, and phosSteroidogenesis appears to parallel or to follow the increase in phatidylserine. Effects of cycloheximide on adrenal phosphatidylserine (X), phosphatidylglycerol (Q), phosphatidylinositol (A), and phosphatidic acid (*) during ongoing (as in Fig. 3) ACTH(1-18) The attainment of steady-state increases in the concentrations of phospholipids in the phosphatidate-polyphosphoinositides-polyglycerophospholipid pathway during continued ACTH stimulation indicates that the production rates for these phospholipids are balanced by their degradation rates. Accordingly, a considerable fraction of phosphatidylinositol (see Table 1 ) is probably converted to 1,2-diacylglycerol, which may be utilized for phosphatidate resynthesis (14, 15) or synthesis of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Thus, a generalized increase in phospholipids may follow, and this could trigger subsequent adrenal hypertrophy. In support of this, phospholipid, protein, and RNA synthesis are tightly coupled in bacteria (11, 13) , and cycloheximide (possibly through effects on phospholipid or protein synthesis) inhibits the ACTH-induced increase in adrenal RNA polymerase (16) .
The observed ACTH-induced increases in the concentrations of phospholipids in the phosphatidate -polyphosphoinositide-polyglycerophospholipid pathway are considerably different from those that accompany increases in phosphatidylinositol breakdown. The latter "phospholipid effect", long recognized (14, 15, 17) , increases phosphatidic acid and polyglycerophospholipids but decreases phosphatidylinositol and the polyphosphoinositides and does not cause net increases in total phospholipids. These differences may be important because inositides, particularly the polyphosphoinositides, bind Ca2+ (18, 19) and decrease membrane fluidity (20) . Consequently, a number of membrane properties may be altered, and the potential for metabolic regulation seems clear. Parathyroid hormone induces changes in kidney cortex phospholipids (21) that are virtually identical to those induced by ACTH in the adrenal cortex [i.e., stimulation through cyclic AMP of the phosphatidate -polyphosphoinositide-polyglycerophospholipid pathway by a cycloheximide-sensitive mechanism (ref. 21 and unpublished observations)]. Since ACTH and parathyrin both utilize cyclic AMP as a "second messenger" (22) (23) (24) , stimulation of the phosphatidate-polyphosphoinositide-polyglycerophospholipid cycle may be a frequent concomitant in cyclic AMP action. In addition, an extremely labile protein may be present in many tissues and may play a pivotal role in phosphatidic acid synthesis and subsequent metabolic regulation during the action of hormones, neurotransmitters, and other agents.
